Effect of vitamin D in the treatment of endometriosis

INTERVENTION: Intervention 1: The intervention group will receive oral vitamin D tablets with a dose of 4000 mg every other day for eight weeks, which will be prepared by Dana Pharmaceutical Company. Intervention 2: The control group will receive oral placebo tablets similar to vitamin D tablets (4000 mg) every other day for eight weeks, which will be prepared by Dana Pharmaceutical Company. CONDITION: Endometriosis. ; Endometriosis PRIMARY OUTCOME: Mean score of painful symptoms of endometriosis. Timepoint: Before intervention and 8 weeks after the start of treatment. Method of measurement: Menstrual painful symptoms questionnaire (ENDOPAIN‐4D). SECONDARY OUTCOME: Adverse events. Timepoint: During the treatment. Method of measurement: Checklist. Average severity of dysmenorrhea. Timepoint: Before intervention and 8 weeks after the start of treatment. Method of measurement: Visual Analog Scale. Quality of lifemean score. Timepoint: Before intervention and 8 weeks after the start of treatment. Method of measurement: Endometriosis Health Profile‐30. The frequency of Gelofen consumption. Timepoint: During the treatment. Method of measurement: Checklist. INCLUSION CRITERIA: Women who have endometriosis and it has been confirmed by laparoscopy. Women with symptomatic endometriosis. Women who are married and sexually active. Vitamin D serum level should be less than 30 ng/dl.